. Author manuscript; available in PMC: 2019 Dec 31.

Published in final edited form as: Am J Gastroenterol. 2010 Feb 9;105(5):1133–1139. doi: 10.1038/ajg.2010.9

Table 5.

Scenarios in which testing did not impact clinical management

	Clinical management	n = 47
Detectable HACA	Increase infliximab	7
	Continue infliximab	4
Therapeutic concentrations	Change to another anti-TNF	10
	Increase infliximab	2
	Continue infliximab despite endoscopic/CTE recurrence	3
Subtherapeutic concentrations	Continue infliximab (same dose)	15
	Change treatment secondary to adverse events^a	6

CTE, computed tomography enterography; HACA, human anti-chimeric antibody; TNF, tumor necrosis factor.

These included delayed hypersensitivity reactions (n = 4), tuberculosis (n = 1), and lymphoma (n = 1).